Peplin into Phase III
Tuesday, 09 September, 2008
Peplin [ASX: PLI] has begun a Phase III trial of its PEP005 gel for solar keratoses, common pre-cancerous skin lesions.
The trial will examine the efficacy of the gel when applied to locations other than the head. It will be simultaneously conducted in sites in Australia and the US.
The trial is being conducted with a Special Protocol Assessment from the US FDA, which ensures that the results of the study may be submitted to the FDA as part of the basis of a new drug application.
Around 250 participants are expected take part in the trial of PEP005, an ingenol mebutate gel.
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
